Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $86,899,803 | $116,295,267 | $121,803,014 | $159,498,868 |
| - Cash | $32,268,000 | $49,065,000 | $66,557,000 | $60,087,000 |
| + Debt | $67,900,000 | $73,973,000 | $29,734,000 | $29,271,000 |
| Enterprise Value | $122,531,803 | $141,203,267 | $84,980,014 | $128,682,868 |
| Revenue | $28,835,000 | $12,766,000 | $15,569,000 | $17,712,000 |
| % Growth | 125.9% | -18% | -12.1% | – |
| Gross Profit | $21,219,000 | $9,664,000 | $14,643,000 | $16,779,000 |
| % Margin | 73.6% | 75.7% | 94.1% | 94.7% |
| EBITDA | $105,000 | -$5,707,000 | $3,179,000 | $8,188,000 |
| % Margin | 0.4% | -44.7% | 20.4% | 46.2% |
| Net Income | -$4,838,000 | -$7,193,000 | $382,000 | $1,017,000 |
| % Margin | -16.8% | -56.3% | 2.5% | 5.7% |
| EPS Diluted | -53.95 | -87.17 | 4.63 | 12.4 |
| % Growth | 38.1% | -1,982.7% | -62.7% | – |
| Operating Cash Flow | -$7,718,000 | -$5,273,000 | $9,952,000 | $7,095,000 |
| Capital Expenditures | -$1,537,000 | -$851,000 | -$303,000 | -$201,000 |
| Free Cash Flow | -$9,255,000 | -$6,124,000 | $9,649,000 | $6,894,000 |